Research Progress of Neutrophil Gelatinase-associated Lipocalin in Coronary Heart Disease

doi:10.12114/j.issn.1007-9572.2020.00.096

Abstract

Abstract: In recent years，the rapid development of cardiac markers has improved the overall level of cardiovascular disease's diagnosis.Research findings have shown that neutrophil gelatinase-associated lipocalin（NGAL），as a marker of acute renal injury（AKI），is closely related to the severity of coronary heart disease，adverse prognosis and the occurrence of future cardiovascular events.NGAL is also a potential marker in coronary heart disease.The purpose of this review is to elucidate the origin and nature of NGAL and the relationship between NGAL and the severity of coronary artery disease，stable coronary heart disease，acute coronary syndrome（ACS）and future coronary heart disease events.And it aims to provide a promising reference direction for the researches of biomarkers in coronary heart disease.

Key words: Coronary disease, Neutrophil gelatinase-associated lipocalin, Biomarkers, Coronary artery disease, Stable coronary heart disease, Acute coronary syndrome, Future coronary heart disease events

摘要： 近年来心脏标志物领域有了飞速的发展，推动了整体心血管疾病诊断水平的提高。研究表明，中性粒细胞明胶酶相关脂质运载蛋白（NGAL）作为急性肾损伤（AKI）的一种标志物，与冠心病患者疾病的严重程度、不良预后及未来心血管事件的发生相关，是冠心病领域的潜力标志物。本文就NGAL的来源与性质及NGAL与冠状动脉病变严重程度、稳定型冠心病、急性冠脉综合征（ACS）、未来冠心病事件的关系的研究进展做一综述，希望能够为冠心病生物标志物领域的研究提供新的参考方向。

关键词: 冠心病, 中性粒细胞明胶酶相关脂质运载蛋白, 生物标志物, 冠状动脉病变, 稳定型冠心病, 急性冠脉综合征, 未来冠心病事件

CUI Xiaohao,YANG Zhiming. Research Progress of Neutrophil Gelatinase-associated Lipocalin in Coronary Heart Disease　[J]. Chinese General Practice, 2020, 23(27): 3492-3495. DOI: 10.12114/j.issn.1007-9572.2020.00.096.
崔小豪,杨志明. 中性粒细胞明胶酶相关脂质运载蛋白在冠心病中的研究进展[J]. 中国全科医学, 2020, 23(27): 3492-3495. DOI: 10.12114/j.issn.1007-9572.2020.00.096.

References

［1］PIEPOLI M F，CORRà U，DENDALE P，et al．Challenges in secondary prevention after acute myocardial infarction：a call for action［J］．Eur J Cardiovasc Nurs，2017，16（5）：369-380．DOI：10.1177/1474515117702594.
［2］KHAWAJA S，JAFRI L，SIDDIQUI I，et al．The utility of neutrophil gelatinase-associated Lipocalin（NGAL）as a marker of acute kidney injury（AKI）in critically ill patients［J］．Biomark Res，2019，7：4．DOI：10.1186/s40364-019-0155-1.
［3］KJELDSEN L，JOHNSEN A H，SENGEL?V H，et al．Isolation and primary structure of NGAL，a novel protein associated with human neutrophil gelatinase［J］．J Biol Chem，1993，268（14）：10425-10432.
［4］PEDERSEN K R，RAVN H B，HJORTDAL V E，et al．Neutrophil gelatinase-associated lipocalin（NGAL）：validation of commercially available ELISA［J］．Scand J Clin Lab Invest，2010，70（5）：374-382．DOI：10.3109/00365513.2010.486868.
［5］HELANOVA K，SPINAR J，PARENICA J.Diagnostic and prognostic utility of neutrophil gelatinase-associated lipocalin（NGAL）in patients with cardiovascular diseases——review［J］．Kidney Blood Press Res，2014，39（6）：623-629．DOI：10.1159/000368474.
［6］PRECEK J，HUTYRA M，KOVáCIK F，et al．Biomarkers of renal function in prognostic stratification of patients with acute coronary syndrome［J］．Cor Vasa，2018，60（2）：e148-154．DOI：10.1016/j.crvasa.2017.05.018.
［7］HEMDAHL A L，GABRIELSEN A，ZHU C Y，et al．Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction［J］．Arterioscler Thromb Vasc Biol，2006，26（1）：136-142．DOI：10.1161/01.ATV.0000193567.88685.f4.
［8］EILENBERG W，STOJKOVIC S，PIECHOTA-POLANCZYK A，et al．Neutrophil gelatinase-associated lipocalin（NGAL）is associated with symptomatic carotid atherosclerosis and drives pro-inflammatory state in vitro［J］．Eur J Vasc Endovasc Surg，2016，51（5）：623-631．DOI：10.1016/j.ejvs.2016.01.009.
［9］SUNG H K，CHAN Y K，HAN M，et al．Lipocalin-2（NGAL）attenuates autophagy to exacerbate cardiac apoptosis induced by myocardial ischemia［J］．J Cell Physiol，2017，232（8）：2125-2134．DOI：10.1002/jcp.25672.
［10］ZOGRAFOS T，HALIASSOS A，KOROVESIS S，et al．Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease［J］．Am J Cardiol，2009，104（7）：917-920．DOI：10.1016/j.amjcard.2009.05.023.
［11］SOYLU K，AKSAN G，NAR G，et al．Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome［J］．Anatol J Cardiol，2015，15（6）：450-455．DOI：10.5152/akd.2014.5513.
［12］KATAGIRI M，TAKAHASHI M，DOI K，et al．Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease［J］．Heart Vessels，2016，31（10）：1595-1602．DOI：10.1007/s00380-015-0776-8.
［13］李超，彭瑜，高涵翔，等．血浆中性粒细胞明胶酶相关脂质运载蛋白水平与急性ST段抬高型心肌梗死病变严重程度的关系［J］．中国循环杂志，2018，33（3）：222-226．DOI：10.3969/j.issn.1000-3614.2018.03.004.
LI C，PENG Y，GAO H X，et al．Relationship between plasma level of neutrophil gelatinase-associated lipocalin and coronary lesion severity in patients with acute ST-elevation myocardial infarction［J］．Chinese Circulation Journal，2018，33（3）：222-226．DOI：10.3969/j.issn.1000-3614.2018.03.004.
［14］MALYSZKO J，BACHORZEWSKA-GAJEWSKA H，MALYSZKO J S，et al．Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease［J］．Nephrology（Carlton），2008，13（2）：153-156．DOI：10.1111/j.1440-1797.2007.00899.x.
［15］PAULSSON J，DADFAR E，HELD C，et al．Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease［J］．Atherosclerosis，2007，192（2）：328-334．DOI：10.1016/j.atherosclerosis.2006.08.003.
［16］CHAKRABARTI S，PATEL K D.Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils［J］．J Leukoc Biol，2005，78（1）：279-288．DOI：10.1189/jlb.1004612.
［17］SIVALINGAM Z，ERIK MAGNUSSON N，GROVE E L，et al．Neutrophil gelatinase-associated lipocalin（NGAL）and cardiovascular events in patients with stable coronary artery disease［J］．Scand J Clin Lab Invest，2018，78（6）：470-476．DOI：10.1080/00365513.2018.1499956.
［18］LINDBERG S，PEDERSEN S H，MOGELVANG R，et al．Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention［J］．J Am Coll Cardiol，2012，60（4）：339-345．DOI：10.1016/j.jacc.2012.04.017.
［19］ZYKOV M V，KASHTALAP V V，BYKOVA I S，et al．Clinical and prognostic value of serum neutrophil gelatinase-associated lipocalin in patients with ST-segment elevation myocardial infarction［J］．Kardiologiia，2016，56（5）：24-29．DOI：10.18565/cardio.2016.5.24-29.
［20］LIM Y M，MOON J Y，MIN D，et al．Serial measurements of neutrophil gelatinase-associated lipocalin：prognostic value in patients with ST-segment elevation myocardial infarction treated with a primary percutaneous coronary intervention［J］．Coron Artery Dis，2017，28（8）：690-696．DOI：10.1097/MCA.0000000000000542.
［21］FAN Y，ZOU C.Prognostic value of neutrophil gelatinase-associated lipocalin in patients with acute ST-segment elevation myocardial infarction：a meta-analysis［J］．Eur J Prev Cardiol，2019，26（4）：444-446．DOI：10.1177/2047487318783254.
［22］NYMO S H，HARTFORD M，UELAND T，et al．Serum neutrophil gelatinase-associated lipocalin（NGAL）concentration is independently associated with mortality in patients with acute coronary syndrome［J］．Int J Cardiol，2018，262：79-84．DOI：10.1016/j.ijcard.2018.03.028.
［23］LAHIRI A，ALEX A G，GEORGE P V.Estimating the prevalence of elevated plasma neutrophil gelatinase associated lipocalin level in patients with acute coronary syndromes and its association with outcomes［J］．Indian Heart J，2018，70（2）：220-224．DOI：10.1016/j.ihj.2017.06.005.
［24］SHALENKOVA M A，MIKHAILOVA Z D，KLIMKIN P F.NGAL as a marker for some extrarenal complications in acute coronary syndrome［J］．Kardiologiia，2018（S3）：19-26.
［25］MARTíNEZ-MARTíNEZ E，BUONAFINE M，BOUKHALFA I，et al．Aldosterone target NGAL（neutrophil gelatinase-associated lipocalin）is involved in cardiac remodeling after myocardial infarction through NFκB pathway［J］．Hypertension，2017，70（6）：1148-1156．DOI：10.1161/HYPERTENSIONAHA.117.09791.
［26］NAKA K K，PAPATHANASSIOU K，BECHLIOULIS A，et al．Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2 diabetes mellitus［J］．Clin Biochem，2018，53：31-37．DOI：10.1016/j.clinbiochem.2017.12.010.
［27］CHONG J J H，PRINCE R L，THOMPSON P L，et al．Association between plasma neutrophil gelatinase-associated lipocalin and cardiac disease hospitalizations and deaths in older women［J］．J Am Heart Assoc，2019，8（1）：e011028．DOI：10.1161/JAHA.118.011028.
［28］FASSETT R G，ROBERTSON I K，BALL M J，et al．Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease：a post hoc analysis of the LORD trial［J］．Nephrol Dial Transplant，2012，27（1）：182-189．DOI：10.1093/ndt/gfr193.
［29］LáBR K，?PINAR J，PARENICA J，et al．Renal functions and prognosis stratification in chronic heart failure patients and the importance of neutrophil gelatinase-associated lipocalin［J］．Kidney Blood Press Res，2018，43（6）：1865-1877．DOI：10.1159/000495819.
［30］CHEN S，CHEN X C，LOU X H，et al．Determination of serum neutrophil gelatinase-associated lipocalin as a prognostic biomarker of acute spontaneous intracerebral hemorrhage［J］．Clin Chim Acta，2019，492：72-77．DOI：10.1016/j.cca.2019.02.009.
［31］MOSCHEN A R，ADOLPH T E，GERNER R R，et al．Lipocalin-2：a master mediator of intestinal and metabolic inflammation［J］．Trends Endocrinol Metab，2017，28（5）：388-397．DOI：10.1016/j.tem.2017.01.003.
［61］MATSUSHITA S，YONEKURA K，MERA K，et al．Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy［J］．J Dermatol，2011，38（10）：996-998．DOI:10.1111/j.1346-8138.2010.01149.x.
［62］BELEZNAY K M，LEVESQUE M A，GILL S.Response to 5-fluorouracil in metastatic extramammary Paget disease of the scrotum presenting as pancytopenia and back pain［J］．Curr Oncol，2009，16（5）：81-83．DOI:10.3747/co.v16i5.374.
［63］TAKAHAGI S，NODA H，KAMEGASHIRA A，et al．Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy［J］．J Dermatol，2009，36（8）：457-461．DOI:10.1111/j.1346-8138.2009.00676.x.
［64］MOCHITOMI Y，SAKAMOTO R，GUSHI A，et al．Extramammary Paget's disease/carcinoma successfully treated with a combination chemotherapy：report of two cases［J］．J Dermatol，2005，32（8）：632-637．DOI:10.1111/j.1346-8138.2005.tb00812.x.
［65］WATANABE Y，HOSHIAI H，UEDA H，et al．Low-dose mitomycin C，etoposide，and cisplatin for invasive vulvar Paget's disease［J］．Int J Gynecol Cancer，2002，12（3）：304-307．DOI:10.1046/j.1525-1438.2002.01126.x.
［66］AL HALLAK M N，ZOUAIN N.Extramammary perianal Paget's disease［J］．Case Rep Gastroenterol，2009，3（3）：332-337．DOI:10.1159/000256382.
［67］ZOLLO J D，ZEITOUNI N C.The Roswell park cancer institute experience with extramammary Paget's disease［J］．Br J Dermatol，2000，142（1）：59-65．DOI:10.1046/j.1365-2133.2000.03242.x.
［68］YE J N，RHEW D C，YIP F，et al．Extramammary Paget's disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid：a case report［J］．Cutis，2006，77（4）：245-250.
［69］ITO T，KAKU Y，NAGAE K，et al．Tumor thickness as a prognostic factor in extramammary Paget's disease［J］．J Dermatol，2015，42（3）：269-275．DOI:10.1111/1346-8138.12764.
［70］KARAM A，DORIGO O.Treatment outcomes in a large cohort of patients with invasive extramammary Paget's disease［J］．Gynecol Oncol，2012，125（2）：346-351．DOI:10.1016/j.ygyno.2012.01.032.
［71］HERREL L A 1，WEISS A D，GOODMAN M，et al．Extramammary Paget's disease in males:survival outcomes in 495 patients［J］.Ann Surg Oncol，2015，22（5）:1625-1630．DOI：10.1245/s10434-014-4139-y.
［72］WANG Z，LU M，DONG G Q，et al．Penile and scrotal Paget's disease:130 Chinese patients with long-term follow-up［J］.BJU Int，2008，102（4）：485-488．DOI:10.1111/j.1464-410X.2008.07575.x.

[1]	WANG Qiushi, LI Hongwei. The Predictive Value of CHA₂DS₂-VASc Score on Major Adverse Cardiovascular Events in Patients with Three Vessels or Left Main Diseases of Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(33): 4130-4136.
[2]	YUAN Dehui, LI Yuhong, XIONG Min, YU Min, MA Ruiliang, YANG Fangfang, YU Qiaozhi, WANG Minghuan. Status and Influencing Factors of Allostatic Load in Pregnant Women at Different Trimesters [J]. Chinese General Practice, 2023, 26(32): 4057-4063.
[3]	LI Yiru, LI Yuhong. Progress in Methods for the Assessment of Allostatic Load and Its Impact on Health [J]. Chinese General Practice, 2023, 26(32): 4051-4056.
[4]	YUAN Mingpei, LIN Yaowang, BEI Weijie, LIU Huadong, DONG Shaohong, SUN Xin. Feasibility of Retrograde Recanalization of Occluded Radial Artery via Distal Transradial Artery Approach: a Single-center Prospective Study [J]. Chinese General Practice, 2023, 26(27): 3373-3377.
[5]	CAI Gaojun, SHI Ganwei, LI Feng, LI Wenhua, YAN Yongmin, XUE Sheliang, XIAO Jianqiang, GU Jun, SONG Yanbin, ZHANG Liuyan, LU Wei, GONG Chun. How to Improve the Success Puncture Rate of Distal Transradial Artery Approach, "Winding Path to the Secluded": Summary of the Experience of More than 2 000 Cases [J]. Chinese General Practice, 2023, 26(27): 3361-3365.
[6]	LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372.
[7]	LAN Yonghao, KE Erqin, HAN Rui, MEI Yingchen, LIU Wei. Percutaneous Coronary Intervention via Distal Transradial Approach: Strengths, Weaknesses, Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(27): 3355-3360.
[8]	GAO Yang, WANG Yunxia, ZHANG You, GAO Chuanyu. Lipid Goal Attainment Rate and Influencing Factors in 45-year-old or Younger Acute Coronary Syndrome Patients with an Ultra-high Risk of Atherosclerotic Cardiovascular Disease after Lipid-lowering Treatment [J]. Chinese General Practice, 2023, 26(27): 3383-3387.
[9]	YAN Haihao, ZHANG Feifei, DANG Yi. Correlation of Remnant Cholesterol with Vulnerable Plaque Characteristics in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2023, 26(26): 3303-3307.
[10]	ZUMURETI ·Abudukeyimu, MA Yanlin, ZHU Kairui, LIU Fang, LI Xia. Correlation of Early Growth Response 3 and Interleukin 6 Expression Levels with Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(24): 3016-3021.
[11]	JI Mengying, LI Yujing, CHEN Xing, DAI Huihua, SUN Ying. Prediction Value of B-ultrasound with Tumor Markers for Malignant Transformation of Mucinous Ovarian Tumors [J]. Chinese General Practice, 2023, 26(24): 3022-3027.
[12]	CHEN Yan, LYU Zhibo, ZHAO Xin. Correlation of Discordance between Remnant Lipoprotein Cholesterol and Non-high-density Lipoprotein Cholesterol and Severity of Coronary Stenosis [J]. Chinese General Practice, 2023, 26(24): 3010-3015.
[13]	XU Ting, JI Minghui, CHEN Yimeng, GAO Yu, ZHU Hanfei, DING Lingyu, XU Qin. Advances in Multiomic Analyses of Frailty Biomarkers in the Elderly [J]. Chinese General Practice, 2023, 26(23): 2871-2876.
[14]	WANG Dan, WANG Jianhui, DONG Jianxiu, CHANG Wenhong, QIN Lu, LIU Qi, CHEN Chen. Effect of an Internet-based Intervention on Motor Behavior in Patients after Percutaneous Coronary Intervention [J]. Chinese General Practice, 2023, 26(21): 2603-2608.
[15]	WANG Zhou, DENG Jinlong, WU Dongfeng. Association between ACAT-1 rs1044925 SNP and Acute Coronary Syndrome and Change of Serum Lipid Level in Response to Atorvastatin Treatment [J]. Chinese General Practice, 2023, 26(21): 2620-2625.